Penetration and accumulation of moxifloxacin in uterine tissue.
Author(s): Stass H, Kubitza D, Aydeniz B, Wallwiener D, Halabi A, Gleiter C
Affiliation(s): Bayer HealthCare AG, Wuppertal, Germany.
Publication date & source: 2008-08, Int J Gynaecol Obstet., 102(2):132-6. Epub 2008 May 27.
OBJECTIVE: To determine whether moxifloxacin penetrates the uterine tissue and accumulates at levels sufficient to eradicate the major pathogens causing pelvic inflammatory disease (PID). METHOD: In a prospective, multicenter, open-label, parallel-group study we determined the concentration of moxifloxacin in plasma and uterine tissue after a single, 400-mg intravenous dose of moxifloxacin. Study participants were randomized for time of tissue sampling, which was performed 1, 2, 4, 7, or 24 hours following the moxifloxacin infusion. RESULTS: Of 43 participants, 40 were randomized to tissue sampling. Moxifloxacin accumulated in uterine tissue and concentrations were highest 1 hour after infusion in both plasma and tissue. Tissue to plasma ratios remained between 1.7 and 2.1 for 24 hours. Moxifloxacin was found to be safe and well tolerated. CONCLUSION: Based on known minimum inhibitory concentration data, the uterine tissue concentrations of moxifloxacin achieved over 24 hours would be sufficient to eradicate the range of bacterial pathogens responsible for PID.
|